Development of Molecularly Driven Targeted Combination Strategies

Targeted therapies are often inadequate when used in isolation as single agents. Combining diverse targeted therapies could optimally impact patient care by overcoming cancer resistance mechanisms. This commentary highlights such combinatorial strategies, including discussion on a recent trial.

Detalles Bibliográficos
Autores principales: Yap, Timothy A., Rodon, Jordi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2017
Materias:
Commentaries
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5728037/
https://www.ncbi.nlm.nih.gov/pubmed/29038233
http://dx.doi.org/10.1634/theoncologist.2017-0402

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5728037/
https://www.ncbi.nlm.nih.gov/pubmed/29038233
http://dx.doi.org/10.1634/theoncologist.2017-0402

Ejemplares similares